Effectiveness of Long-Term Treatment with Brodalumab on Anxiety or Depressive Symptoms in Japanese Patients with Psoriasis: The ProLOGUE Study

被引：8

作者：

Ohata, Chika ^{[1
,10
]}

Kanai, Yasumasa ^{[2
]}

Murotani, Kenta ^{[3
]}

Yamazaki, Fumikazu ^{[4
]}

Takahashi, Hidetoshi ^{[5
]}

Tada, Yayoi ^{[6
]}

Mabuchi, Tomotaka ^{[7
]}

Mizutani, Yoko ^{[8
]}

Nomura, Takanobu ^{[2
]}

Imafuku, Shinichi ^{[9
]}

机构：

[1] Kurume Univ, Dept Dermatol, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan

[2] Kyowa Kirin Co Ltd, Med Affairs, 1-9-2 Otemachi,Chiyoda Ku, Tokyo 1000004, Japan

[3] Kurume Univ, Biostat Ctr, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan

[4] Kansai Med Univ, Dept Dermatol, 2-5-1 Shin Machi, Hirakata, Osaka 5731010, Japan

[5] Takagi Dermatol Clin, Nishi 3 Minami 4-16, Obihiro, Hokkaido 0800013, Japan

[6] Teikyo Univ, Dept Dermatol, Sch Med, 2-11-1 Kaga,Itabashi Ku, Tokyo 1738605, Japan

[7] Tokai Univ, Dept Dermatol, Sch Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan

[8] Gifu Univ, Dept Dermatol, Grad Sch Med, 1-1 Yanagido, Gifu, Gifu 5011193, Japan

[9] Fukuoka Univ, Fac Med, Dept Dermatol, 7-45-1 Nanakuma,Jonan Ku, Fukuoka 8140180, Japan

[10] Osaka Gen Med Ctr, Dept Dermatol, 3-1-56 Bandaihigashi, Sumiyoshi, Osaka 5588558, Japan

来源：

DERMATOLOGY AND THERAPY | 2023年 / 13卷 / 04期

关键词：

Anxiety symptoms; Brodalumab; Depressive symptoms; Health-related quality of life; Psoriasis; LIFE QUALITY INDEX; PREVALENCE; MODERATE;

D O I：

10.1007/s13555-023-00909-z

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

IntroductionEvidence on treatment effectiveness in patients with psoriasis having anxiety or depressive symptoms helps shared decision-making. This single-arm, open-label, prospective study-ProLOGUE-was conducted to assess the effectiveness of brodalumab on self-assessed anxiety and depressive symptoms in Japanese patients with psoriasis.MethodsPatients aged >= 18 years with plaque psoriasis without peripheral arthritis symptoms who had responded inadequately to current therapies were enrolled at 15 Japanese facilities and received brodalumab 210 mg subcutaneously.ResultsA total of 73 patients were enrolled (male, 82%; median age, 54 years). The proportion of patients without anxiety symptoms changed significantly from baseline (72.6%) to weeks 12 (88.9%, p = 0.008) and 48 (87.7%, p = 0.02); the proportion of patients without depressive symptoms did not change significantly. The Generalized Anxiety Disorder-7 score (median [quartile(Q)1-Q3], 1.0 [0.0-5.0] at baseline; 0.0 [0.0-2.0] at week 12, p = 0.008; and 0.0 [0.0-1.0] at week 48, p = 0.007) and Patient Health Questionnaire-8 score (median [Q1-Q3], 2.0 [0.0-4.0] at baseline; 1.0 [0.0-4.0] at week 12, p = 0.03; and 0.0 [0.0-2.0] at week 48, p = 0.004) significantly decreased after treatment. The median Psoriasis Area and Severity Index scores after treatment were < 1, irrespective of the presence of baseline anxiety or depressive symptoms. At week 12, the health-related quality of life was more impaired in patients with versus without baseline depressive symptoms, which largely resolved at week 48.ConclusionsBrodalumab treatment resulted in the reduction of the levels of self-assessed anxiety and depressive symptoms in Japanese patients with psoriasis. Unlike anxiety symptoms, depressive symptoms did not resolve completely with brodalumab treatment. Patients with psoriasis having depressive symptoms may require long-term treatment.

引用

页码：1039 / 1052

页数：14

共 40 条

[1] Global burden of psoriasis - comparison of regional and global epidemiology, 1990 to 2017 [J].